Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats

Hypertension

Volumn 34, Issue 1, 1999, Pages 138-143

  Fortuño, Ana ^a   Muñiz, Paula ^a   Ravassa, Susana ^a   Rodriguez, Jose Antonio ^a   Fortuño, Ma Antonia ^a   Zalba, Guillermo ^a   Díez, Javier ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Angiotensin II; Calcium; Furosemide; Irbesartan; Muscle, smooth, vascular; Rats, inbred SHR; Torasemide

Indexed keywords

ANGIOTENSIN; CALCIUM ION; FUROSEMIDE; IRBESARTAN; TORASEMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; THORACIC AORTA; VASCULAR RING; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

EID: 0345211624     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.34.1.138     Document Type: Article

References (38)

1. Dahlöf B, Lindhölm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet. 1991;338:1281-1285.
2. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405-412.
3. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC-VI). Arch Intern Med. 1997;157:2413-2446.
4. Pecker MS. Pathophysiologic effects and strategies for long-term diuretic treatment of hypertension. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. New York, NY: Raven Press; 1990:2117-2130.
5. Zsoter TT. Mechanism of antihypertensive action of prolonged administration of hydrochlorothiazide in rabbit and dog. Circ Res. 1970;27: 717-725.
6. Weinberger MH, Ramsdell JW, Rosner DR, Geddes JJL. Effect of chlorothiazide and sodium on vascular responsiveness to angiotensin II. Am J Physiol. 1972;223:1049-1052.
7. Weidmann P, Beretta-Piccoli C, Meier A, Keusch G, Glueck Z. Untersuchungen zum antihypertensiven mechanismus von diuretika. In: Knick F, Schey A, eds. Diuretika 11. Munich, Germany: Wolf; 1981:58-76.
8. Wittner M, Di Stefano A, Schlatter E, Delarge J, Greger R. Torasemide inhibits NaCl reabsorption in the thick ascending limb of the loop of Henle. Pflügers Arch. 1986;407:611-614.
9. Wittner M, Di Stefano A, Wangemann P, Delarge J, Liegeois JF, Greger R. Analogues of torasemide-structure function relationships-experiments in the thick ascending limb of the loop of Henle of rabbit nephron. Pflügers Arch. 1987;408:54-62.
10. Greger R. Inhibition of active NaCl reabsorption in the thick ascending limb of the loop of Henle by torasemide. Arzneimittelförschung. 1988; 38:151-152.
11. Dupont AG, Schoors D, Six RO, Vanhaelst L. Antihypertensive efficacy of low dose torasemide in essential hypertension: a placebo-controlled study. J Hum Hypertens. 1988;2:265-268.
12. Achhammer I, Metz P. Low dose loop diuretics in essential hypertension: experience with torasemide. Drugs. 1991;41(suppl 3):80-91.
13. Luft FC. Torasemide in the treatment of arterial hypertension. J Cardiovasc Pharmacol. 1993;22(suppl 3):S32-S39.
14. Barthelmebs M, Stephan D, Fontaine C, Grima M, Imbs JL. Vascular effects of loop diuretics: an in vivo and in vitro study in the rat. Naunyn Schmiedebergs Arch Pharmacol. 1994;349:209-216.
15. Pickkers P, Dormans TPJ, Russel FGM, Hughes AD, Thien T, Schaper N, Smit P. Direct vascular effects of furosemide in humans. Circulation. 1997;96:1847-1852.
16. Carmines PK. Segment-specific effect of chloride channel blockade on rat renal arteriolar contractile responses to angiotensin II. Am J Hypertens. 1995;8:90-94.
17. Takenaka T, Kanno Y, Kitamura Y, Hayashi K, Suzuki H, Saruta T. Role of chloride channels in afferent arteriolar constriction. Kidney Int. 1996; 50:864-872.
18. Diez J, Panizo A, Hernández M, Vega F, Sola I, Fortuño MA, Pardo J. Cardiomyocyte apoptosis and cardiac angiotensin-converting enzyme in spontaneously hypertensive rats. Hypertension. 1997;30:1029-1034.
19. Neusser M, Tepel M, Golinski P, Holthues J, Spieker C, Zhu Z, Zidek W. Different calcium storage pools in vascular smooth muscle cells from spontaneously hypertensive and normotensive Wistar-Kyoto rats. J Hypertens. 1994;12:533-538.
20. 2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1982; 260:3440-3450.
21. Bartsch W, Dörge L, Kling W, Schaumann W, Gebhardt G, Stegmeier K, Sponer G. Investigations on the inhibitory activity of torasemide on vasoconstriction induced by KCl, noradrenaline, endothelin, or U 46619, and on platelet aggregation induced by collagen, U 44069, or ADP. In: Puschett JB, Greenberg AC, eds. Diuretics IV: Chemistry, Pharmacology and Clinical Applications. New York, NY: Elsevier; 1993:349-353.
22. 2+ fluxes in aortic smooth muscle. Hypertension. 1993;22:806-811.
23. Peach MJ. Renin-angiotensin system: biochemistry and mechanism of action. Physiol Rev. 1997;57:313-370.
24. Smith JB. Angiotensin-receptor signaling in cultured vascular smooth muscle cells. Am J Physiol. 1986;250:F759-F769.
25. Timmermans PB, Wong PC, Chin AT, Herblin WF, Benfield P, Carini DI, Lee RJ, Wexler RR, Saya JA, Smith RD. Angiotensin II receptor and angiotensin II receptor antagonists. Pharmacol Rev. 1993;45:205-251.
26. Stamler JS, Dzau VJ, Loscalzo J. The vascular smooth muscle cell. In: Loscalzo J, Greger MA, Dzau VJ, eds. Vascular Medicine. Boston, Mass: Little/Brown; 1996:69-116.
27. Somlyo AP, Somlyo AV. Vascular smooth muscle. II: pharmacology of normal and hypertensive vessels. Pharmacol Rev. 1970;22:251-353.
28. Bolton TB. Mechanisms of action of transmitters and other substances on smooth muscle. Physiol Rev. 1970;59:606-718.
29. Wittner M, Di Stefano A, Wangemann P, Greger R. How do loop diuretics act? Drugs. 1991;41(suppl 3):1-13.
30. Schlatter E, Greger R, Weidtke C. Effect of "high ceiling" diuretics on active salt transport in the cortical thick ascending limb of Henle's loop of rabbit kidney: correlation of chemical structure and inhibitory potency. Pflügers Arch. 1983;396:210-217.
31. Tokushige A, Kino M, Tamura H, Hopp L, Searle BM, Aviv A. Bumetanide-sensitive sodium-22 transport in vascular smooth muscle cells of the spontaneously hypertensive rat. Hypertension. 1986;8: 379-385.
32. De Mendonca M, Knorr A, Grichois ML, Ben Ishay D, Garay RP, Meyer P. Erythrocytic sodium transport systems in primary and secondary hypertension in the rat. Kidney Int. 1982;21:S69-S75.
33. + cotransport system as a marker of antihypertensive activity of new torasemide derivatives. Eur J Pharmacol. 1992; 219:285-294.
34. + cotransport function in a group of patients with essential hypertension. Eur J Clin Invest. 1983;13:311-320.
35. White CR, Elton TS, Shoemaker RL, Brock TA. Calcium-sensitive chloride channels in vascular smooth muscle cells. Proc Soc Exp Biol Med. 1995;208:255-262.
36. - channels by organic and inorganic blockers in vascular smooth muscle cells. Pflügers Arch. 1991;418:204-213.
37. Yamanaga K, Uchida T, Kido H, Hayashi K, Watanabe M. Torasemide, but not furosemide, increases intracellular cAMP and cGMP content in the aorta of the renal hypertensive rat. J Pharm Pharmacol. 1992;44: 64-65.
38. Liguori A, D'Armiento FP, Casini A, Leccese M, Napoli C. Loop diuretics enhanced secretion of prostacyclin in vitro and in patients with heart failure. J Am Coll Cardiol. 1997;29:152A. Abstract.